Investigating the molecular mechanisms of altered NCAPG expression in the pathogenesis of high-risk multiple myeloma
Katia Yazji
Katia received the Breakthrough Cancer Summer Scholarship, enabling her to conduct research under the supervision of Prof. Siobhan Glavey at Royal College of Surgeons in Ireland during the summer.
Multiple myeloma (MM) is an aggressive cancer of the bone marrow, and it affects approximately 300 people every year in Ireland. Myeloma is incurable and survival varies greatly, some patients survive more than 10 years, and some survive less than 2 years. For patients with very poor survival, we need to improve available treatments to see improved outcomes. Recently research has shown that in MM, a gene called NCAPG is increased in patients with very poor survival.
This project aims to investigate why NCAPG is increased and how we could better treat patients with this gene abnormality. To do this, models of MM will be used in the laboratory to perform several experiments, one of which will involve testing new drugs that could work to improve survival for patients with increased NCAPG. This research will contribute to the ongoing studies at RCSI to improve outcomes for myeloma patients.
Back
Start year
2021
End year
2021
Principal Investigator
Prof. Siobhan Glavey
Researcher
Katia Yazji
Institution
Royal College of Surgeons in Ireland
Grant Funding
Breakthrough Cancer Research Summer Scholarship
Linked Breakthrough Research Priorities
Increase research investment into poor prognosis cancers and currently incurable cancers prioritising lung, oesophageal, ovarian, pancreatic, brain, liver and stomach cancers.
Fund the discovery and development of new therapeutics, surgical approaches and technologies, including biological and immune approaches, to improve cancer treatment.
Fund research which aims to improve the effectiveness or specificity of current cancer therapies including investing in biomarkers discovery, nutrition and therapeutic delivery.